Premature Labor (Tocolysis) - Pipeline Review, H2 2020
Premature Labor (Tocolysis) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor - Pipeline Review, H2 2020, provides an overview of the Premature Labor (Women's Health) pipeline landscape.
Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Labor - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Premature Labor (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Premature Labor (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Premature Labor (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor - Pipeline Review, H2 2020, provides an overview of the Premature Labor (Women's Health) pipeline landscape.
Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Labor - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Premature Labor (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Premature Labor (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Premature Labor (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Premature Labor (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Premature Labor (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Premature Labor (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Women's Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Premature Labor (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Premature Labor (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Premature Labor (Tocolysis) - Overview
Premature Labor (Tocolysis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Premature Labor (Tocolysis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
Dare Bioscience Inc
GlaxoSmithKline Plc
ILIAS Biologics Inc
Lipocine Inc
ObsEva SA
Premature Labor (Tocolysis) - Drug Profiles
hydroxyprogesterone caproate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBE-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
progesterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein for Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
retosiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Labor (Tocolysis) - Dormant Projects
Premature Labor (Tocolysis) - Discontinued Products
Premature Labor (Tocolysis) - Product Development Milestones
Featured News & Press Releases
Aug 19, 2020: Dar? Bioscience announces funding award notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to support DARE-FRT1 phase 1 human clinical study for the prevention of preterm birth
Jan 15, 2020: ObsEva to provide update on OBE022 at JP Morgan Healthcare Conference in San Francisco
Oct 10, 2019: Dar? Bioscience announces a poster presentation on a pharmacokinetic study of DARE-FRT1, in development for sustained-release progesterone therapy for pregnancy maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo
Jul 26, 2019: ObsEva reports positive feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
Mar 13, 2019: ObsEva to present OBE022 clinical data for treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
Jan 22, 2019: ObsEva SA reports initial good safety of OBE022 in pregnant women with preterm labour and announces start of part B of the PROLONG trial
Oct 30, 2018: Dare Bioscience to present preclinical data of DARE-FRT1 at AAPS 2018 meeting
Mar 01, 2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting
Jun 29, 2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting
Jun 26, 2017: Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022
Mar 17, 2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Premature Labor (Tocolysis) - Overview
Premature Labor (Tocolysis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Premature Labor (Tocolysis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
Dare Bioscience Inc
GlaxoSmithKline Plc
ILIAS Biologics Inc
Lipocine Inc
ObsEva SA
Premature Labor (Tocolysis) - Drug Profiles
hydroxyprogesterone caproate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBE-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
progesterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein for Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
retosiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Labor (Tocolysis) - Dormant Projects
Premature Labor (Tocolysis) - Discontinued Products
Premature Labor (Tocolysis) - Product Development Milestones
Featured News & Press Releases
Aug 19, 2020: Dar? Bioscience announces funding award notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to support DARE-FRT1 phase 1 human clinical study for the prevention of preterm birth
Jan 15, 2020: ObsEva to provide update on OBE022 at JP Morgan Healthcare Conference in San Francisco
Oct 10, 2019: Dar? Bioscience announces a poster presentation on a pharmacokinetic study of DARE-FRT1, in development for sustained-release progesterone therapy for pregnancy maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo
Jul 26, 2019: ObsEva reports positive feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
Mar 13, 2019: ObsEva to present OBE022 clinical data for treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
Jan 22, 2019: ObsEva SA reports initial good safety of OBE022 in pregnant women with preterm labour and announces start of part B of the PROLONG trial
Oct 30, 2018: Dare Bioscience to present preclinical data of DARE-FRT1 at AAPS 2018 meeting
Mar 01, 2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting
Jun 29, 2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting
Jun 26, 2017: Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022
Mar 17, 2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Premature Labor (Tocolysis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Premature Labor (Tocolysis) - Pipeline by Dare Bioscience Inc, H2 2020
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2020
Premature Labor (Tocolysis) - Pipeline by ILIAS Biologics Inc, H2 2020
Premature Labor (Tocolysis) - Pipeline by Lipocine Inc, H2 2020
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2020
Premature Labor (Tocolysis) - Dormant Projects, H2 2020
Premature Labor (Tocolysis) - Discontinued Products, H2 2020
Number of Products under Development for Premature Labor (Tocolysis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Premature Labor (Tocolysis) - Pipeline by Dare Bioscience Inc, H2 2020
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2020
Premature Labor (Tocolysis) - Pipeline by ILIAS Biologics Inc, H2 2020
Premature Labor (Tocolysis) - Pipeline by Lipocine Inc, H2 2020
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2020
Premature Labor (Tocolysis) - Dormant Projects, H2 2020
Premature Labor (Tocolysis) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Premature Labor (Tocolysis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Dare Bioscience Inc
GlaxoSmithKline Plc
ILIAS Biologics Inc
Lipocine Inc
ObsEva SA
Number of Products under Development for Premature Labor (Tocolysis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Dare Bioscience Inc
GlaxoSmithKline Plc
ILIAS Biologics Inc
Lipocine Inc
ObsEva SA
